Glycotope GmbH Email Format

Biotechnology ResearchBerlin, Germany11-50 Employees

Glycotope GmbH is a Berlin-based biotechnology research company that pursues tumor-specific monoclonal antibodies using a proprietary platform. It integrates glycobiology expertise with antibody development to advance first-in-class antibody-based therapeutics for immuno-oncology. The company targets tumor-associated carbohydrate structures or protein/carbohydrate glyco-epitopes (GlycoTargets) to enable multiple modalities, including naked antibodies, bispecifics, antibody-drug conjugates, cellular therapies, or fusion proteins. To date, Glycotope has identified more than 200 GlycoTargets and has several antibodies under development. The organization is located at 10 Robert-roessle-street, Berlin, 13125 Germany, and employs between 11 and 50 people. In recent years, Glycotope has engaged in collaborations and asset transactions, including the July 2024 sale of assets to PentixaPharm, and has previously partnered with companies such as Daiichi Sankyo and LegoChem Biosciences.

Sign up for free to view info

Company overview Employee directory